In order to compared the performance of FDCSP and SRGN with known FDC-S markers in the differential with soft tissue tumors, we tested CD21, CD23, CD35, CXCL13, Clusterin, Claudin 4 and Podoplanin in our groups of tumors and controls. This evidence concerns the gene CR1 and soft tissue neoplasm.